Advisory Panel Reviews Are Too Lenient On Advanced Tech, Report Finds
This article was originally published in The Gray Sheet
Executive Summary
FDA advisory panels convened to review new devices and pharmaceuticals are not taking their responsibilities seriously enough, the National Research Center for Women & Families charges in an Aug. 28 report